Abstract
The introduction of tumor necrosis factor (TNF)-α inhibitors dramatically improved the management of psoriasis. Some newer or investigational biologics with different mechanisms of action have demonstrated noninferiority or superiority to etanercept, the first self-injectable anti-TNF-α agent to become available in the United States. Nonetheless, TNF-α inhibitors are likely to remain a mainstay of therapy for many years.
Keywords:
Efficacy; investigational agents; psoriasis; psoriatic arthritis; safety; tumor necrosis factor inhibitors.
2016 published by Frontline Medical Communications.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adalimumab / administration & dosage*
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Arthritis, Psoriatic / drug therapy
-
Cardiovascular Diseases / prevention & control
-
Certolizumab Pegol / administration & dosage*
-
Clinical Trials as Topic
-
Clinical Trials, Phase III as Topic
-
Dermatologic Agents / administration & dosage*
-
Dermatologic Agents / adverse effects
-
Etanercept / administration & dosage*
-
Humans
-
Infliximab / administration & dosage*
-
Piperidines / administration & dosage
-
Psoriasis / drug therapy*
-
Pyrimidines / administration & dosage
-
Pyrroles / administration & dosage
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Ustekinumab / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Dermatologic Agents
-
Piperidines
-
Pyrimidines
-
Pyrroles
-
Tumor Necrosis Factor-alpha
-
guselkumab
-
tofacitinib
-
golimumab
-
Infliximab
-
ixekizumab
-
secukinumab
-
Ustekinumab
-
Adalimumab
-
Etanercept
-
Certolizumab Pegol